Skip to main content
SpringerLink
Log in

Effect of Vonoprazan, a Potassium-Competitive Acid Blocker, on the 13C-Urea Breath Test in Helicobacter pylori-Positive Patients

  • Original Article
  • Published:
Digestive Diseases and Sciences Aims and scope Submit manuscript

A Correction to this article was published on 10 June 2021

This article has been updated

Abstract

Background and Aim

Vonoprazan (VPZ) is a new oral potassium-competitive acid blocker that has recently become available. The aim of this study was to investigate the effects of VPZ on the urease activity of H. pylori as measured by the 13C-urea breath test (13C-UBT).

Patients and Methods

A total of 60 patients (26 men, 34 women; mean age 53.2 ± 13.6 years) who were diagnosed as H. pylori-positive were recruited. The patients were randomly allocated to three treatment groups: lansoprazole (LPZ) 30 mg (n = 20), VPZ 20 mg (n = 20) once daily for 3 weeks, or the control group (n = 20). The 13C-UBT was carried out at baseline and after 3 weeks of treatment, and the baseline and after treatment results then compared. Δ13C‰ ≥ 2.5‰ was considered H. pylori-positive.

Results

Four patients failed to complete the medication and were omitted from the analysis; data from the LPZ group (n = 18), VPZ group (n = 18), and control group (n = 20) were analyzed. The control group showed no significant change in 13C-UBT data between baseline and the completion of 3-week treatment (baseline: 26.6 ± 23.0‰, completion: 21.1 ± 13.1‰). The 13C-UBT data at week 3 were significantly decreased in both the VPZ group (baseline: 32.8 ± 22.7‰, completion: 7.6 ± 9.2‰, p = 0.0002) and the LPZ group (baseline: 41.8 ± 33.4‰; completion: 9.6 ± 8.8‰, p = 0.0006) compared to baseline.

Conclusions

VPZ treatment reduced the value of UBT, warning that UBT for patients with VPZ treatment should be evaluated carefully.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

Change history

References

  1. Ohara S, Kato M, Asaka M, et al. The Ubit-100 13CO2 infrared analyzer: comparison between infrared analyzer spectrometric analysis and mass spectrometric analysis. Helicobacter. 1998;3:49–53.

    Article  CAS  PubMed  Google Scholar 

  2. Chey WD, Spybrook M, Carpenter S, et al. Prolong effect of omeprazole on the 14C-urea breath test. Am J Gastroenterol. 1996;91:89–92.

    CAS  PubMed  Google Scholar 

  3. Chey WD, Woods M, Scheiman JM, et al. Lansoprazol and ranitidine affect the accuracy of the 14C-urea breath test by a pH-dependent mechanism. Am J Gastroenterol. 1997;92:446–450.

    CAS  PubMed  Google Scholar 

  4. Laine L, Estrada R, Trujillo M, et al. Effect of proton pump inhibitor therapy on diagnostic testing for Helicobacter pylori. Ann Intern Med. 1998;129:547–550.

    Article  CAS  PubMed  Google Scholar 

  5. El-Nujumi A, Hilditch TE, Williams C, et al. Current or recent proton pump inhibitor therapy markedly impairs the accuracy of the[14C]urea breath test. Eurl Gastroenterol Hepatol. 1998;10:759–764.

    Article  CAS  Google Scholar 

  6. Connor SJ, Seow F, Ngu MC, et al. The effect of dosing with omeprazole on the accuracy of the 13C-urea breath test in Helicobacter pylori-infected subjects. Aliment Pharmacol Ther. 1999;13:1287–1293.

    Article  CAS  PubMed  Google Scholar 

  7. Savarino V, Bisso G, Pivari M, et al. Effect of gastric acid suppression on 13C-urea breath test; comparison of ranitidine with omeprazole. Aliment Pharmacol Ther. 2000;14:291–297.

    Article  CAS  PubMed  Google Scholar 

  8. Chey WD, Chathadi KV, Montague J, et al. Intragastric acidification reduces the occurrence of false-negative urea breath test results in patients taking a proton pump inhibitor. Am J Gastroenterol. 2001;96:1028–1032.

    Article  CAS  PubMed  Google Scholar 

  9. Murakami K, Sato R, Okimoto T, et al. Influence of anti-ulcer drugs used in Japan on the result of 13C-urea breath test for the diagnosis of Helicobacter pylori infection. J Gastroenterol. 2003;38:937–941.

    Article  CAS  PubMed  Google Scholar 

  10. Adachi K, Fujishiro H, Mihara T, et al. Influence of lansoprazole, famotidine, roxatidine and rebamipide administration on the urea breath test for the diagnosis of Helicobacter pylori infection. J Gastroenterol Hepatol. 2003;18:168–171.

    Article  PubMed  Google Scholar 

  11. Graham DY, Opekun AR, Hammoud F, et al. Studies regarding the mechanism of false negative urea breath tests with proton pump inhibitors. Am J Gastroenterol. 2003;98:1005–1009.

    Article  CAS  PubMed  Google Scholar 

  12. Chey WD. Proton pump inhibitors and the urea breath test: how long is long enough? Am J Gastroenterol. 1997;92:720–721.

    CAS  PubMed  Google Scholar 

  13. Jenkins H, Sakurai Y, Nishimura A, et al. Randomised clinical trial: safety, tolerability, pharmacokinetics and pharmacodynamics of repeated doses of TAK-438 (vonoprazan), a novel potassium-competitive acid blocker, in healthy male subjects. Aliment Pharmacol Ther. 2015;41:636–648.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  14. Ohara S, Kato M, Saito M, Fukuda S, et al. Comparison between a new 13C-urea breath test, using a film-coated tablet, and the conventional 13C-urea breath test for the detection of Helicobacter pylori infection. J Gastroenterol. 2002;39:621–628.

    Google Scholar 

  15. Parente F, Sainaghi M, Sangaletti O, et al. Different effects of short-term omeprazole, lansoprazole or pantoprazole on the accuracy of the (13)C-urea breath test. Aliment Pharmacol Ther. 2002;16:553–557.

    Article  CAS  PubMed  Google Scholar 

  16. Bravo LE, Realpe JL, Campo C, et al. Effects of acid suppression and bismuth medications on the performance of diagnostic tests for Helicobacter pylori infection. Am J Gastroenterol. 1999;94:2380–2383.

    Article  CAS  PubMed  Google Scholar 

  17. Graham DY, Klein PD, Evans DJ Jr, et al. Campylobacter pylori detected noninvasively by the 13C-urea breath test. Lancet. 1987;23:1174–1177.

    Article  Google Scholar 

  18. Gisbert JP, Pajares JM. Review article: 13C-urea breath test in the diagnosis of Helicobacter pylori infection—a critical review. Aliment Pharmacol Ther. 2004;20:1001–1017.

    Article  CAS  PubMed  Google Scholar 

  19. Vaira D, Holton J, Menegatti M. Review article: invasive and non-invasive tests for Helicobacter pylori infection. Aliment Pharmacol Ther. 2000;14:13–22.

    Article  PubMed  Google Scholar 

  20. Garza-González E, Perez-Perez GI, Maldonado-Garza HJ. A review of Helicobacter pylori diagnosis, treatment, and methods to detect eradication. World J Gastroenterol. 2014;20:1438–1449.

    Article  PubMed  PubMed Central  Google Scholar 

  21. Sharma BK, Santana IA, et al. Intragastric bacterial activity and nitrosation before, during, and after treatment with omeprazole. Br Med J. 1984;289:717–719.

    Article  CAS  Google Scholar 

  22. Shirin H, Levine A, Shevah O, et al. Eradication of Helicobacter pylori can be accurately confirmed 14 days after termination of triple therapy using a high-dose citric acid-based 13C urea breath test. Digestion. 2005;71:208–212.

    Article  CAS  PubMed  Google Scholar 

  23. Savarino V, Bisso G, Pivari M, et al. Effect of gastric acid suppression on 13C-urea breath test: comparison of ranitidine with omeprazole. Aliment Pharmacol Ther. 2000;14:291–297.

    Article  CAS  PubMed  Google Scholar 

  24. Cutler AF, Elnaggar M, Brooks E, et al. Effect of standard and high dose ranitidine on 13C-urea breath test results. Am J Gastroenterol. 1998;93:1297–1299.

    Article  CAS  PubMed  Google Scholar 

  25. Connor SJ, Ngu MC, Katelaris PH. The impact of short-term ranitidine use on the precision of the 13C-urea breath test in subjects infected with Helicobacter pylori. Eur J Gastroenterol Hepatol. 1999;11:1135–1138.

    Article  CAS  PubMed  Google Scholar 

  26. Rektorschek M, Weeks D, Sachs G, et al. Influence of pH on metabolism and urease activity of Helicobacter pylori. Gastroenterology. 1998;115:628–641.

    Article  CAS  PubMed  Google Scholar 

  27. Scott DR, Marcus EA, Weeks DL, et al. Mechanisms of acid resistance due to the urease system of Helicobacter pylori. Gastroenterology. 2002;123:187–195.

    Article  CAS  PubMed  Google Scholar 

  28. Meyer-Rosberg K, Scott DR, Rex D, Melchers K, et al. The effect of environmental pH on the proton motive force of Helicobacter pylori. Gastroenterology. 1996;111:886–900.

    Article  CAS  PubMed  Google Scholar 

  29. Shin JM, Inatomi N, Munson K, et al. Characterization of a novel potassium-competitive acid blocker of the gastric H, K-ATPase, 1-[5-(2-fluorophenyl)-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl]-N-methylmethanamine monofumarate (TAK-438). J Pharmacol Exp Ther. 2011;339:412–420.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  30. Scott DR, Munson KB, Marcus EA, et al. The binding selectivity of vonoprazan (TAK-438) to the gastric H + , K + -ATPase. Aliment Pharmacol Ther. 2015;42:1315–1326.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  31. Hori Y, Imanishi A, Matsukawa J, et al. 1-[5-(2-Fluorophenyl)-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl]-N-methylmethanamine monofumarate (TAK-438), a novel and potent potassium-competitive acid blocker for the treatment of acid-related diseases. J Pharmacol Exp Ther. 2010;335:231–238.

    Article  CAS  PubMed  Google Scholar 

  32. Matsukawa J, Hori Y, Nishida H, et al. A comparative study on the modes of action of TAK-438, a novel potassium-competitive acid blocker, and lansoprazole in primary cultured rabbit gastric glands. Biochem Pharmacol. 2011;81:1145–1151.

    Article  CAS  PubMed  Google Scholar 

  33. Murakami K, Sakurai Y, Shiino M, et al. Vonoprazan, a novel potassium-competitive acid blocker, as a component of first-line and second-line triple therapy for Helicobacter pylori eradication: a phase III, randomised, double-blind study. Gut. Epub. 03/02/2016.

  34. Ashida K, Sakurai Y, Nishimura A, et al. Randomised clinical trial: a dose-ranging study of vonoprazan, a novel potassium-competitive acid blocker, vs. lansoprazole for the treatment of erosive oesophagitis. Aliment Pharmacol Ther. 2015;42:685–695.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  35. Ashida K, Sakurai Y, Nishimura A, et al. Randomised clinical trial: a dose-ranging study of vonoprazan, a novel potassium-competitive acid blocker, vs. lansoprazole for the treatment of erosive oesophagitis. Aliment Pharmacol Ther. 2015;42:685–695.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  36. Kagami T, Sahara S, Ichikawa H, et al. Potent acid inhibition by vonoprazan in comparison with esomeprazole with reference to CYP2C19 genotype. Aliment Pharmacol Ther. 2016;43:1048–1059.

    Article  CAS  PubMed  Google Scholar 

  37. Hunt RH, Scarpignato C. Potassium-competitive acid blockers (P-CABs): are they finally ready for prime time in acid-related disease? Clin Transl Gastroenterol. 2015;6:e119.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  38. Nakao M, Malfertheiner P. Growth inhibitory and bactericidal activities of lansoprazole compared with those of omeprazole and pantoprazole against Helicobacter pylori. Helicobacter. 1998;3:21–27.

    Article  CAS  PubMed  Google Scholar 

  39. Sakurai Y, Mori Y, Okamoto H, et al. Acid-inhibitory effects of vonoprazan 20 mg compared with esomeprazole 20 mg or rabeprazole 10 mg in healthy adult male subjects—a randomised open-label cross-over study. Aliment Pharmacol Ther. 2015;42:719–730.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Gastroenterology, Department of Internal Medicine, Hyogo College of Medicine, 1-1, Mukogawa-cho, Nishinomiya, Hyogo, 663-8501, Japan

    Mayu Takimoto, Toshihiko Tomita, Takahisa Yamasaki, Shota Fukui, Masato Taki, Takuya Okugawa, Takashi Kondo, Tomoaki Kono, Katsuyuki Tozawa, Yoshio Ohda, Tadayuki Oshima, Hirokazu Fukui, Jiro Watari & Hiroto Miwa

  2. Department of Internal Medicine, Nishinomiya Kyoritsu Neurosurgical Hospital, Nishinomiya, Hyogo, Japan

    Eitatsu Arai

Authors
  1. Mayu Takimoto
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Toshihiko Tomita
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Takahisa Yamasaki
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Shota Fukui
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Masato Taki
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Takuya Okugawa
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Takashi Kondo
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Tomoaki Kono
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Katsuyuki Tozawa
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Eitatsu Arai
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Yoshio Ohda
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Tadayuki Oshima
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. Hirokazu Fukui
    View author publications

    You can also search for this author in PubMed Google Scholar

  14. Jiro Watari
    View author publications

    You can also search for this author in PubMed Google Scholar

  15. Hiroto Miwa
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Toshihiko Tomita.

Ethics declarations

Conflict of interest

None.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Takimoto, M., Tomita, T., Yamasaki, T. et al. Effect of Vonoprazan, a Potassium-Competitive Acid Blocker, on the 13C-Urea Breath Test in Helicobacter pylori-Positive Patients. Dig Dis Sci 62, 739–745 (2017). https://doi.org/10.1007/s10620-016-4439-0

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10620-016-4439-0

Keywords

Search

Navigation